16.40 USD
▲+0.30+1.86%
盘后 16.17 -1.40%
2026-11-19
市值
$901.14M
市盈率
—
EPS
-2.18
股息率
—
52 周区间
13.96 – 34.19
成交量
384.78K
Beta
—
目标价
35.88
52W 低 13.9652W 高 34.19
价格走势
公司简介
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225A...
关联新闻
- Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks
A pullback in the AI trade has created opportunities for bargain-hunting investors, according to analysts at Bank of America.